.webp)
Even the most natural things need a little help sometimes
If you’re experiencing occasional constipation, you’re not alone1! It is one of the most common gastro-intestinal inconvenient disorders affecting up to 31% of the general adult population and up to 44.5% of the older adult populations2. The experts at Dulcolax® are giving you all the information you need.
%201%20(4).webp)
Dulcolax is the #1 non-prescriptive laxative brand in the Philippines12
Available in more than 90 countries
Clinically proven
Dulcolax® contains bisacodyl and is a stimulant laxative for the relief of constipation symptoms. With its dual action it induces water and salt transport into the gut which hydrates the stool and makes it easier to pass. These products were also shown to be very safe3
Improves quality of life
Dulcolax® has been shown to relieve constipation symptoms such as bloating, hard stool and gassiness, allowing you to feel more in control and less stressed. It activates your digestive system and initiates a comfortable poo so you could feel clean and fresh again inside and out.
Works in harmony with your body
Dulcolax tablets works best when taken at night for overnight relief. Dulcolax works naturally with your body to support the natural gut rhythm so you can feel good when you wake up!
Widely tolerable
Nonprescription laxatives like Dulcolax® are generally safe and well tolerated. Please consult a doctor if you are pregnant or breastfeeding.10
Dulcolax® range of solutions
Dulcolax® products help your digestive system get moving, with different reliefs available: overnight relief and fast relief so you can feel good inside and out!
-
Dulcolax® Coated Tablets
Stimulates bowel movements by helping facilitate transit and evacuation of the stool overnight (between 6-12 hours)
Dulcolax® Adult Suppositories 10 mg
Stimulates bowel movements by helping facilitate transit and evacuation of the stool in about 20-30 minutes.
Dulcolax® Pedia Suppositories 5 mg
Stimulates bowel movements by helping facilitate transit and evacuation of the stool in about 20-30 minutes.
-
Dulcolax® Coated Tablets
Stimulates bowel movements by helping facilitate transit and evacuation of the stool overnight (between 6-12 hours)
-
Dulcolax® Adult Suppositories 10 mg
Stimulates bowel movements by helping facilitate transit and evacuation of the stool in about 20-30 minutes.
Dulcolax® Pedia Suppositories 5 mg
Stimulates bowel movements by helping facilitate transit and evacuation of the stool in about 20-30 minutes.
Which Dulcolax® product is the one for you?
Everyone deserves to find the one. Learn about Dulcolax® products and choose the right one to help you to successfully poo.
Stay informed
Constipation symptoms such as bloatedness, gassiness and hard dry stool can be extremely bothersome and persistent. Because we know how frustrating and stressful these periods can be, we can help identify the causes for constipation and how to prevent it.
What are the daily habits that can cause constipation?
Our daily life habits have a strong impact on our body functions, including our digestive system. The result may be that you get constipated. But a little goes a long way. Making simple changes to your lifestyle habits is the first step for most people.
How can getting older cause constipation?
As we get older, the bowel muscles in the digestive tract need a little bit more time to move food and stool through the intestines. The resulting constipation is a frequently reported bowel symptom in the elderly with considerable impact on quality of life. Understand how age can change your body and how to adapt to help yourself feel better.
Constipation during pregnancy – a common phenomenon
During pregnancy, certain hormones increase and trigger many changes in the body. Pregnant women frequently suffer from difficult and infrequent bowel movements, hard and dry stools, abdominal pain and discomfort. Although not dangerous in most cases, symptoms of constipation should be addressed properly.
- Wald A, Scarpignato C, Mueller-Lissner S, Kamm MA, Hinkel U, Helfrich I, Schuijt C, Mandel KG. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008 Oct 1;28(7):917-30.
- Werth, B.L. Epidemiology of constipation in adults: Why estimates of prevalence differ. J. Epidemiol. Res. 2019, 5, 37–49.
- Kamm, M. A. et. al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin.Gastroenterol.Hepatol. 2011; 9(7):577-583.
- Kienzle-Horn S, Vix JM, Schuijt C, Comparison of bisacodyl and sodium picosulfate in the treatment of chronic constipation. Curr Med Res Opin 2007;23:891-9
- Nelson AD, Camilleri M, Chirapongsathorn S, et al. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut. 2017;66(9):1611-1622.
- Müller-Lissner S, Richter E, Eberlin M, Weigmann H, Mück T, Kamm, M. Bisacodyl and Sodium Picosulfate Improve Bowel Function and Quality of Life in Patients with Chronic Constipation—Analysis of Pooled Data from Two Randomized Controlled Trials. Open Journal of 2017. Gastroenterology, 7, 32-43. http://www.scirp.org/journal/ojgas
- Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005 Jan;100(1):232-42.
- Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, Simrén M, Lembo A, Young-Fadok TM, Chang L. Chronic constipation. Nat Rev Dis Primers. 2017 Dec 14;3:17095.
- Corsetti M, Landes S, Lange R. Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation. Neurogastroenterol Motil. 2021 Mar 9:e14123. doi: 10.1111/nmo.14123. Epub ahead of print. PMID: 33751780.
- Harms RW. Mayo Clinic guide to a healthy pregnancy. 2011. Mayo Foundation for medical education and research.
- Andresen V, Layer P. Medical Therapy of Constipation: Current Standards and Beyond. Visc Med. 2018;34(2):123‐127.
- Sanofi PPI Certification www.ducolax.ph/Sanofi PPI Certification A06A A06B MAT Oct 2021 (002) signed.pdf
